| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Chief Financial Officer
2 companies
Tomsicek Michael John is a Chief Financial Officer at CRISPR Therapeutics AG with holdings across 2 companies. Recent SEC Form 4 filings include 1 buy and 7 sells.
Estimated insider holdings value: $1.5M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 19, 2022 | MIST Milestone Pharmaceuticals Inc. | Director | Buy | 15,000 | $5.32 | $79,800.00 | New | -21.0% | -44.6% | |
| Aug 6, 2021 | CRSP Crispr Therapeutics AG | Chief Financial Officer | Sale+OE | 25,000 | $138.52 | $3,462,926.36 | -71.9% | -32.0% | -40.5% | |
| Sep 1, 2020 | CRSP Crispr Therapeutics AG | Chief Financial Officer | Sale+OE | 12,000 | $92.26 | $1,107,068.00 | -47.6% | - | - | |
| Aug 3, 2020 | CRSP Crispr Therapeutics AG | Chief Financial Officer | Sale+OE | 12,000 | $86.74 | $1,040,918.53 | -65.7% | - | - |